 |
|
|
| |
Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084
|
| |
| |
IAS 2021 July 8-22
Mark A. Marzinke1, Sinead Delany-Moretlwe2, Yaw Agyei1, Estelle Piwowar-Manning1, Peter Anderson3, Craig Hendrix4, Scott Rose5, Jennifer Farrior5, Adeola Adeyeye6, Brett Hanscom7, Alex Rinehart8, James Rooney9, Myron Cohen10, Mina Hosseinipour10, 11, Susan H. Eshleman1, on behalf of the HPTN 084 study team.
1 Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, United States, 2 Wits RHI, University of the Witwatersrand, Johannesburg, South Africa, 3 University of Colorado, Anschutz Medical Campus, Denver, United States, 4 Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, United States, 5 FHI360, Durham, United States, 6 Division of AIDS, National Institute for Allergy and Infectious Diseases, Rockville, United States, 7 Statistical Center for HIV/AIDS Research Prevention, Fred Hutchinson Cancer Research Institute, Seattle, United States, 8 ViiV Healthcare, Durham, United States, 9 Gilead Sciences, Foster City, United States, 10 University of North Carolina (UNC) at Chapel Hill, Chapel Hill, United States, 11 UNC Project-Malawi, Lilongwe, Malawi
|
| |
|
|
|
|
|
